Challenges in Designing Pre-Clinical Toxicity Studies for Oligonucleotides & Their Clinical Relevance

Time: 11:30 am
day: Day One

Details:

  • Lessons learned from approved oligonucleotide therapeutics (ONTs)
  • Lack of specific regulatory guidance for development of ONTs
  • Considerations for development of ONTs

Speakers: